|
2.6 Etiologie - Environnement
|
|
|
Mystery cancers are cropping up in children in aftermath of Fukushima [Science]
|
|
|
|
|
|
“It
is inappropriate to compare the data from the Fukushima screening
program with cancer registry data from the rest of Japan where there is,
in general, no such large-scale screening,” Richard Wakeford, an
epidemiologist at the University of Manchester in the United Kingdom,
wrote on behalf of 11 members of a WHO expert working group on Fukushima
health consequences.
|
|
|
|
|
|
|
|
3.4.1 Chimioprévention - aspirine
|
|
|
|
Quantifying Aspirin’s Reduction in Cancer Risk [NY Times]
|
|
|
|
|
|
“Based
on our estimates,” Dr. Chan said, “we think that regular aspirin use
could prevent almost 30,000 cases of gastrointestinal cancers a year,
which account for almost 25 percent of all cancer deaths. So I think
that’s pretty substantial.”
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
ASCO Commends IOM Report “Biomarker Tests for Molecularly Targeted Therapies” [ASCO]
|
|
|
|
|
|
CancerLinQ
will fulfill the IOM’s recommendation for the implementation of a rapid
learning system that will track long-term patient outcomes related to
the use of biomarker tests and targeted therapies. However, the current
lack of interoperability among clinical databases and with genomic data
sets is a major roadblock to achieving the promise of precision
medicine.
|
|
|
|
|
|
|
|
5. Traitements
|
|
|
Fighting Cancer By Putting Tumor Cells On A Diet [NPR]
|
|
|
|
|
|
He
points out that data supporting the ketogenic diet in cancer are
limited – and further that rigorous dietary studies are incredibly hard
to pull off. "The drug companies aren't going to fund these types of
trials," he says. "They can't make money marketing a diet."
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
Jimmy Carter says he no longer needs cancer drug treatment [AP]
|
|
|
|
|
|
Medical
experts have called Keytruda and similar immune therapy drugs
"game-changing" for patients with melanoma. But the drugs are relatively
new, and doctors are still learning about how they should be used and
for how long, said Dr. Len Lichtenfeld, deputy chief medical officer for
the American Cancer Society.
|
|
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
5.9 AACR
|
|
|
AACR Annual Meeting 2016 Preview [AACR]
|
|
|
|
|
|
Watch
a preview of the AACR Annual Meeting 2016 from AACR President 2015-2016
José Baselga, MD, PhD, physician-in-chief and chief medical officer at
Memorial Sloan Kettering Cancer Center in New York, and AACR Annual
Meeting 2016 Program Committee Chairperson Scott A. Armstrong, MD, PhD,
director of the Memorial Sloan Kettering Leukemia Center.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
|
|
6.7.2 Applis
|
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|